Inventor · disambiguated record
Andrew P. Degnan
Also filed as: DEGNAN ANDREW P
19 granted patents·6 pending applications·81 citations·filing 2003–2024
92Inventor score
Top patents by PatentIndex Score
25 records- 0188US7314883B2Anti-migraine treatmentsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Jan 1, 2008·12 cites·36 claims
- 0287US7842808B2Anti-migraine spirocyclesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Nov 30, 2010·13 cites·36 claims
- 0386US7772244B2Therapeutic agents for the treatment of migraineBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 10, 2010·12 cites·14 claims
- 0483US11548870B2Compounds useful as inhibitors of helios proteinBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Jan 10, 2023·1 cites·12 claims
- 0583US9695176B2Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jul 4, 2017·6 cites·9 claims
- 0680US7569578B2Heterocyclic anti-migraine agentsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Aug 4, 2009·14 cites·31 claims
- 0779US8026257B2Substituted heterocyclic ethers and their use in CNS disordersBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Sep 27, 2011·4 cites·17 claims
- 0879US7220862B2Calcitonin gene related peptide receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted May 22, 2007·11 cites·36 claims
- 0975US9725449B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Aug 8, 2017·2 cites·17 claims
- 1074US9751879B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 5, 2017·1 cites·13 claims
- 1173US11166959B2Isofuranone compounds useful as HPK1 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 9, 2021·1 cites·15 claims
- 1271US8691821B2Oxazolidinones as modulators of mGluR5DEGNAN ANDREW P·Filed 2011·Granted Apr 8, 2014·3 cites·14 claims
- 1368USRE49735EOxazolidinones as modulators of MGLUR5BRISTOL MYERS SQUIBB CO·Filed 2021·Granted Nov 28, 2023·0 cites·16 claims
- 1467US9688669B2Oxazolidinones as modulators of mGluR5BRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jun 27, 2017·1 cites·12 claims
- 1563US2025084056A1Substituted oxoisoindolinyl piperidine-2,6-dione compoundsBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1661US8383821B2NK-1 and serotonin transporter inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Feb 26, 2013·0 cites·9 claims
- 1758US12486267B2Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosisBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Dec 2, 2025·0 cites·19 claims
- 1855US7632861B2Substituted heterocyclic ethers and their use in CNS disordersBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Dec 15, 2009·0 cites·15 claims
- 1953US2007249607A1Nk-1 and serotonin transporter inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 2051US2009018163A1Substituted Heterocyclic Ethers and Their Use in CNS DisordersBRISTOL MYERS SQUIBB CO·Filed 2008·Application pending·0 cites
- 2147US7179926B2Aryloxyalkylamine NK-1/SSRI inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Feb 20, 2007·0 cites·13 claims
- 2247US2004063735A1Calcitonin gene related peptide receptor antagonistsFiled 2003·Application pending·0 cites
- 2347US2018030057A1SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTSBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 2446US2016318928A1Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 2537US10174024B25H-pyrido[3,2-B]indole compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 8, 2019·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Andrew P. Degnan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →